

Tocilizumab for the management of immune mediated blockade

Journal of Oncology Pharmacy Practice

25, 551-557

DOI: [10.1177/1078155217745144](https://doi.org/10.1177/1078155217745144)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3528.	1.8	143
2	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
3	Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. , 2018, 6, 153.		29
4	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.4	230
5	Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e180.	1.3	74
7	A Review of Immune-Mediated Adverse Events in Melanoma. <i>Oncology and Therapy</i> , 2019, 7, 101-120.	1.0	23
8	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 2100-2111.	2.9	202
9	Emerging trends in immunotherapy for pediatric sarcomas. <i>Journal of Hematology and Oncology</i> , 2019, 12, 78.	6.9	59
10	Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. , 2019, 7, 169.		28
11	Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience. <i>Seminars in Immunology</i> , 2019, 44, 101325.	2.7	30
12	Testing Immune-Related Adverse Events in Cancer Immunotherapy. <i>Clinics in Laboratory Medicine</i> , 2019, 39, 669-683.	0.7	3
13	Immune checkpoint inhibitor–related luminal GI adverse events. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 881-892.	0.5	24
14	Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 813-822.	1.3	221
15	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. <i>BMC Cancer</i> , 2019, 19, 558.	1.1	106
16	Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. <i>RMD Open</i> , 2019, 5, e000906.	1.8	59
17	Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. <i>Immunotherapy</i> , 2019, 11, 1527-1531.	1.0	12
18	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988419.	1.4	62
19	Checkpoint Inhibitor–Associated Autoimmunity. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.5	0

#	ARTICLE	IF	CITATIONS
21	Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, 197-202.	1.9	12
22	Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus. <i>Internal Medicine</i> , 2020, 59, 569-572.	0.3	8
23	An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors. <i>Digestion</i> , 2020, 101, 60-65.	1.2	12
24	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	0.8	52
25	Management of the Adverse Effects of Immune Checkpoint Inhibitors. <i>Vaccines</i> , 2020, 8, 575.	2.1	29
26	Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice. <i>Current Opinion in Oncology</i> , 2020, 32, 603-612.	1.1	5
27	Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. <i>Frontiers in Oncology</i> , 2020, 10, 1785.	1.3	35
28	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. <i>Communications Biology</i> , 2020, 3, 571.	2.0	31
29	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 25-34.	0.4	0
30	Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting. <i>JACC: CardioOncology</i> , 2020, 2, 491-502.	1.7	20
31	Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. <i>Leukemia Research Reports</i> , 2020, 14, 100228.	0.2	2
32	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
33	Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?. <i>Pharmaceuticals</i> , 2020, 13, 166.	1.7	16
34	Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. <i>Medicina (Lithuania)</i> , 2020, 56, 377.	0.8	15
35	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	5.1	74
36	Programmed cell death 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 299-304.	0.7	10
37	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020, 11, 2077-2086.	0.8	1
38	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1555.	1.3	5

#	ARTICLE	IF	CITATIONS
39	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
41	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Review of Clinical Immunology, 2020, 16, 1185-1204.	1.3	23
42	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
43	Angiotensinâ€converting enzyme 2 (<scp>ACE2</scp>), <scp>SARSâ€CoV</scp>â€2 and the pathophysiology of coronavirus disease 2019 (<scp>COVID</scp>â€19). Journal of Pathology, 2020, 251, 228-248.	2.1	791
44	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	18.1	684
45	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Current Oncology Reports, 2020, 22, 56.	1.8	23
46	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
47	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
48	The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population. Current Oncology Reports, 2020, 22, 60.	1.8	31
49	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. Autoimmunity Reviews, 2020, 19, 102595.	2.5	44
50	Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2020, 26, 326-340.	1.2	10
51	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
52	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sciences, 2020, 10, 345.	1.1	38
53	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. Clinical Lung Cancer, 2020, 21, e547-e550.	1.1	13
54	Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanomaâ€”An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer. International Journal of Molecular Sciences, 2020, 21, 2020.	1.8	18
55	Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy, 2020, 12, 269-273.	1.0	188
56	Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology, 2020, 17, 504-515.	12.5	189
57	Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology, 2020, 72, 315-329.	3.6	131

#	ARTICLE	IF	CITATIONS
58	Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. , 2020, 8, e000842.		126
59	SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a mini review. Pathogens and Disease, 2020, 78, .	0.8	55
60	The Impact of COVID-19 on Cancer Risk and Treatment. Cellular and Molecular Bioengineering, 2020, 13, 285-291.	1.0	33
61	Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. Cancer Immunology, Immunotherapy, 2020, 69, 1101-1112.	2.0	13
62	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	1.8	310
63	A review of cancer immunotherapy toxicity. Ca-A Cancer Journal for Clinicians, 2020, 70, 86-104.	157.7	753
64	The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. Current Opinion in Rheumatology, 2020, 32, 175-183.	2.0	1
65	Commentary: Obesity: The “Achilles heel” for COVID-19?. Metabolism: Clinical and Experimental, 2020, 108, 154251.	1.5	182
66	Autoimmune complications of immunotherapy: pathophysiology and management. BMJ, The, 2020, 369, m736.	3.0	79
68	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
69	Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19. Cancer Discovery, 2020, 10, 775-778.	7.7	28
70	COVID-19 and the Heart. Circulation Research, 2020, 126, 1443-1455.	2.0	574
71	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Annals of Oncology, 2020, 31, 724-744.	0.6	129
72	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. Journal of Oncology Pharmacy Practice, 2021, 27, 739-746.	0.5	18
73	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors “is it time for a paradigm shift?. Clinical Rheumatology, 2021, 40, 1687-1695.	1.0	15
74	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. Cellular and Molecular Immunology, 2021, 18, 829-841.	4.8	21
75	Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacology and Immunotoxicology, 2021, 43, 1-7.	1.1	26
76	Tocilizumab for COVID-19 Pneumonia in a Patient With Non “Small-cell Lung Cancer Treated With Chemoimmunotherapy. Clinical Lung Cancer, 2021, 22, e67-e69.	1.1	11

#	ARTICLE	IF	CITATIONS
77	Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles. , 2021, , 309-321.		0
78	Review of immune checkpoint inhibitors in immuno-oncology. <i>Advances in Pharmacology</i> , 2021, 91, 111-139.	1.2	43
79	Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 84-94.	0.3	0
80	Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis. , 2021, , 273-291.		0
81	Revisiting immunogenic cell death to improve treatment response in cancer. , 2021, , 65-90.		4
82	SARS-COV-2 infection and lung tumor microenvironment. <i>Molecular Biology Reports</i> , 2021, 48, 1925-1934.	1.0	22
83	The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. <i>Frontiers in Oncology</i> , 2021, 11, 625872.	1.3	25
84	Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. <i>Cancers</i> , 2021, 13, 652.	1.7	19
85	Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 183-186.	0.5	4
86	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events" A Comprehensive Review. <i>Frontiers in Oncology</i> , 2020, 10, 585311.	1.3	69
87	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 537-547.	1.0	9
88	Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy. <i>Genomics</i> , 2021, 113, 564-575.	1.3	12
89	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	1.8	18
90	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	21.5	208
91	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. <i>Trends in Immunology</i> , 2021, 42, 293-311.	2.9	62
92	IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285.		32
93	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	2.4	25
94	Inflammatory markers in autoimmunity induced by checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1623-1630.	1.2	24

#	ARTICLE	IF	CITATIONS
95	Peripheral blood interleukin 6, interleukin 10, and T lymphocyte levels are associated with checkpoint inhibitor induced pneumonitis: a case report. <i>Acta Oncologica</i> , 2021, 60, 813-817.	0.8	6
96	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
97	Cytokine storm induced by a PD1 inhibitor in a renal transplant patient. <i>American Journal of Transplantation</i> , 2021, 21, 2616-2618.	2.6	8
98	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. <i>Journal of Investigative Medicine</i> , 2021, 69, 1281-1286.	0.7	0
99	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , 2021, 13, 2931.	1.7	19
100	Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report. <i>Thoracic Cancer</i> , 2021, 12, 2214-2216.	0.8	5
101	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
102	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. <i>Nature Medicine</i> , 2021, 27, 1646-1654.	15.2	65
103	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698832.	1.3	27
105	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , 2021, 1, 253-263.	0.6	11
106	Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1711-1720.	1.2	22
107	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	1.4	52
108	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	1.0	41
109	Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	18
110	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 720759.	1.3	3
111	Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma. <i>Internal Medicine</i> , 2021, 60, 3025-3029.	0.3	10
112	Cutaneous adverse events caused by immune checkpoint inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 956-966.	0.6	59
113	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021, 157, 214-224.	1.3	62

#	ARTICLE	IF	CITATIONS
114	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. SSRN Electronic Journal, 0, , .	0.4	0
115	Checkpoint Inhibitors and Hepatotoxicity. Biomedicines, 2021, 9, 101.	1.4	17
116	Immune-Related Adverse Events: Pneumonitis. Advances in Experimental Medicine and Biology, 2020, 1244, 255-269.	0.8	38
117	The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thoracic Cancer, 2020, 11, 835-839.	0.8	43
118	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. , 2020, 8, e000892.		43
119	Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System. Journal of Immunotherapy and Precision Oncology, 2019, 2, 65-73.	0.6	8
120	Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1287-1290.	2.3	5
121	Immuno-oncologic care during COVID-19: Challenges and opportunities for improving clinical care and investigation. , 2021, 2, 75-82.		1
122	Checkpoint inhibitor pneumonitis: Short review of literature and case report. Memo - Magazine of European Medical Oncology, 0, , 1.	0.3	3
123	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Frontiers in Pharmacology, 2021, 12, 743582.	1.6	14
124	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. Biomedicines, 2021, 9, 1484.	1.4	10
125	The Use of Checkpoint Inhibitors in Classical Hodgkin's Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center's Experience). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 307-315.	0.1	1
126	Differential diagnosis of pneumonia in pediatric patients with oncohematological disease in condition of new coronavirus infection COVID-19. Russian Journal of Pediatric Hematology and Oncology, 2020, 7, 104-111.	0.1	1
127	Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. Clinical Pulmonary Medicine, 2020, 27, 183-192.	0.3	0
130	Hepatobiliary and Pancreatic Adverse Events. Advances in Experimental Medicine and Biology, 2021, 1342, 339-355.	0.8	6
131	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	0.8	4
132	Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. , 2022, 10, e003551.		19
133	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics, 2022, 19, 848-863.	2.1	10

#	ARTICLE	IF	CITATIONS
134	Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature. <i>Frontiers in Immunology</i> , 2022, 13, 807050.	2.2	30
135	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	1.6	8
136	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. <i>Allergology International</i> , 2022, 71, 169-178.	1.4	34
137	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	12.5	360
138	Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 43.	1.6	4
139	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
140	Checkpoint inhibitor/interleukin-6 based combination therapy of cancer. <i>Cancer Medicine</i> , 2022, 11, 2934-2943.	1.3	25
141	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	1.4	8
142	Novel Immunotherapies for Osteosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 830546.	1.3	25
143	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
144	Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. <i>Clinical Cancer Research</i> , 2022, 28, 1250-1257.	3.2	11
147	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
148	Analysis of the mechanisms of development of neurorheumatological consequences of COVID-19 and the possibility of their pharmacological correction. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 92-98.	0.1	1
149	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	7.7	115
150	IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. <i>Cancer Cell</i> , 2022, 40, 450-451.	7.7	8
151	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. <i>ESMO Open</i> , 2022, 7, 100474.	2.0	3
152	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	1.7	2
153	Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives. <i>Journal of Inflammation Research</i> , 0, Volume 15, 3105-3118.	1.6	6

#	ARTICLE	IF	CITATIONS
154	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Instituteâ€”Cancer Therapy Evaluation Program. <i>Journal of Clinical Oncology</i> , 2022, 40, 3439-3452.	0.8	24
155	Immune checkpoint inhibitorâ€”related cholangiopathy: Novel clinicopathological description of a multiâ€”centre cohort. <i>Liver International</i> , 2023, 43, 147-154.	1.9	16
156	Clinical Patterns and Follow-Up of Inflammatory Arthritis and Other Immune-Related Adverse Events Induced by Checkpoint Inhibitors. A Multicenter Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	9
157	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. <i>Biomedicines</i> , 2022, 10, 1334.	1.4	5
158	Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
159	Current status and prospects of IL-6â€”targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 575-592.	1.3	10
160	Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1928-1942.	0.6	6
161	Clinical Outcomes after Immunotherapies in Cancer Setting during COVID-19 Era: A Systematic Review and Meta-Regression. <i>Reports</i> , 2022, 5, 31.	0.2	0
162	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
163	The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	16
164	Immune checkpoint Inhibitorâ€”Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 109, 102440.	3.4	28
165	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
166	Gastroenterology (GI). , 2022, , 81-96.		0
167	Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
168	Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R). <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
169	Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 142-147.	0.4	6
170	External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
171	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4

#	ARTICLE	IF	CITATIONS
172	Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	4
173	COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. , 2022, 10, e005111.		17
174	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
175	Autoimmune and autoinflammatory manifestations in inborn errors of immunity. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2022, 22, 343-351.	1.1	3
176	Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. <i>Translational Lung Cancer Research</i> , 2022, 11, 1835-1846.	1.3	2
178	Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 5977.	1.0	2
179	Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 2360-2368.	0.7	1
180	Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. <i>RMD Open</i> , 2022, 8, e002612.	1.8	6
181	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. <i>Thoracic Cancer</i> , 2022, 13, 3420-3430.	0.8	5
182	Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. , 2022, 10, e005635.		11
183	Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 1217-1238.	0.6	204
184	Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2289-2305.	1.3	6
185	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1
186	Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). <i>European Journal of Cancer</i> , 2023, 180, 125-133.	1.3	7
187	Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
188	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
190	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.2	1
191	Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. <i>Cancers</i> , 2023, 15, 1170.	1.7	0

#	ARTICLE	IF	CITATIONS
192	How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles. <i>Cancers</i> , 2023, 15, 1324.	1.7	1
193	Management of the adverse effects of cancer immunotherapy with a focus on the respiratory and nervous systems. <i>Journal of the Korean Medical Association</i> , 2023, 66, 116-122.	0.1	0
194	Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
195	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
196	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitorsâ€™A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	1.8	7
197	Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
198	Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. <i>European Journal of Cancer</i> , 2023, 187, 36-57.	1.3	1
199	Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer. <i>Current Oncology</i> , 2023, 30, 3672-3683.	0.9	1
200	Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. , 2023, 11, e006398.		22
201	Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
202	Tacrolimus for the Management of Delayed Onset and Treatment-Refractory Immune-Related Hepatitis. <i>ACG Case Reports Journal</i> , 2023, 10, e01007.	0.2	2
203	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. <i>Pathology Research and Practice</i> , 2023, 247, 154473.	1.0	1
216	Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 720-725.	0.4	2
223	Cytokine Response to Nanoparticles Bearing Nucleic Acid Cargo. <i>Studies in Mechanobiology, Tissue Engineering and Biomaterials</i> , 2023, , 229-266.	0.7	0
226	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
235	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.0	0